Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous deferoxamine.
A new regimen of 24-hr ambulatory continuous intravenous infusion of deferoxamine (CIV DFO) through central venous ports was instituted in nine patients aged (mean +/- SD) 22.4 +/- 5.8 years over a period of 15.7 +/- 7.3 months. Central venous infusion sites were changed weekly in the clinic, eliminating the necessity for reconstitution of DFO and needle insertion at home. Because CIV DFO could be interrupted only by medical personnel, patient compliance was documented accurately; patients administered 93.0% +/- 3.2% of CIV DFO prescribed. Mean urinary iron excretion on CIV DFO (66.8 +/- 50.4 mg/24 hr) was significantly greater than that quantitated during 12-hr equivalent-dose subcutaneous DFO infusions (23.4 +/- 18.3 mg/24 hr; P less than 0.025). Mean serum ferritin declined by 71% over the treatment period (P less than 0.005). This regimen confers the advantages of uninterrupted exposure to DFO, is associated with excellent patient compliance, and should be considered in any patient with severe iron overload and erratic compliance with DFO.
Olivieri
N F
NF
Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Berriman
A M
AM
Tyler
B J
BJ
Davis
S A
SA
Francombe
W H
WH
Liu
P P
PP
D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care / Q000379:methods* / Q000592:standards*; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005293:Ferritins / Q000097:blood; D006801:Humans; D007262:Infusions, Intravenous; D007279:Injections, Subcutaneous; D007501:Iron / Q000652:urine*; D008099:Liver / Q000502:physiology; D013789:Thalassemia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology
D005293:Ferritins; D007501:Iron; D003676:Deferoxamine